
Editorial: Eating disorder crisis is plaguing kids and stealing childhoods
Children, as young as seven, starving themselves.
Boys who exercise themselves to exhaustion, obsessed with attaining the perfect physique.
Girls who send photographs of themselves to friends to scrutinise, poring over them for 'imperfections', the lumps and bumps of impending womanhood problems to be wished away.
Young adults who obsess over eating 'clean', or who lurch from diet fad to diet fad, distorting their relationship with food and depriving themselves of nutrients in the process.
Kids who should think of their bodies only in terms of their function — their ability to run, jump, play — comparing themselves to the Ozempic-aided super frail frames of celebrities and finding themselves wanting.
These are the new faces of our national body image crisis. It's an issue that touches every family with young people in some way, whether they realise it or not.
The harm comes on a spectrum.
On the mild end, it's the teenager who looks at themselves in dissatisfaction, wishing they were just a bit thinner, a bit taller or a bit more muscular.
At the extreme end, it's children being admitted to hospital for severe anorexia, bulimia or exercise addiction.
Those kids at the extreme end of the spectrum are turning up more and more in our hospitals and medical clinics, brought there by desperately worried parents.
Unless you've been there yourself, it's impossible to imagine the heartbreak these parents feel as they watch their children literally fade away before them.
They're powerless to help their kids break out of the prison that is the hatred they feel towards their own bodies.
This isn't a new problem. We've known about the dangers of distorted body image for decades.
The drivers have shifted. It's no longer glossy magazines pointing out in lurid detail every 'flaw' on a celebrity's body.
It's online, on dedicated 'pro-ana' communities, and it's the avalanche of images on their Instagram and TikTok feeds that reinforce the notion that they aren't good enough.
And, in some cases, it's us.
It's the parent who complains about their weight creep, and announces a new diet or exercise regimen. And it can be the school that heavily polices the content of lunchboxes, inadvertently teaching kids that food can be 'bad' and something to be feared.
These well-meaning interventions and casual comments can have an impact far greater — and more dangerous — than we realise.
It's a wicked challenge, and all of us with young people in our lives play a role in addressing it. Better training for educators in our schools, better resources treatment centres in our health systems, and greater awareness among parents of the dangers and drivers.
Butterfly Foundation 1800 ED HOPE
Lifeline 13 11 14

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Courier-Mail
5 hours ago
- Courier-Mail
Australian OnlyFans star Koby Falks, 42, dies suddenly
Don't miss out on the headlines from Entertainment. Followed categories will be added to My News. Australian OnlyFans star Koby Falks has passed away at the age of just 42. The adult content creator, who has a combined following of over half a million on social media and his adult platform passed away in the last few days, according to a post made on his official Instagram. 'Koby Falks, better known to his family and friends as Anthony Cox, passed away earlier this week,' read the heartbreaking post that was shared by his partner, Sam Brownwell. 'He was loved by many and will be missed. If this post has affected you, please reach out to Lifeline at 13 11 14.' The adult star's official cause of death has not yet been revealed. Australian OnlyFans creator Koby Falks has tragically died. Picture: Instagram Falks' long-term partner shared the news on social media. Picture: Instagram In a heartfelt post on his own page, Brownell shared his grief, expressing eternal love for his late partner, writing: 'I will love you always.' Matthew Leigh, founder of the Melbourne-based PR firm that Falks was signed to, shared an emotional Instagram following the tragic news alongside the hashtag #MentalHealthMatters. 'Though our time working together was brief, the impact Koby had was anything but small. From the moment we connected, I was struck by his warmth, his charisma, and his incredible professionalism. He was organised, kind-hearted, and deeply respectful — the kind of person you instantly felt grateful to work with. The adult content creator had built up a huge following online. Picture: Instagram. Falks was originally from North Queensland. Picture: Supplied 'It was an honour to represent his remarkable body of work and to witness first-hand the power of his presence, both on and off screen. His ability to connect with people, not just here in Australia but across the world, was something truly special. Koby wasn't just a client — he was a light, a creative force, and a genuinely beautiful soul. He went on to call the adult film star a 'trailblazer', saying: 'Never did I imagine I would be writing such a post, especially for someone I had the privilege of managing. And I sincerely hope I never have to again. To Koby's family, his close friends, and his extended 'family' of fans and followers — my deepest condolences. We have lost a trailblazing creative spirit far too soon. But I truly believe his light and legacy will continue shining brightly above.' Originally published as Australian porn star star Koby Falks, 42, dies suddenly


The Advertiser
7 hours ago
- The Advertiser
Nick Kyrgios suffers fresh injury setback
Nick Kyrgios's Wimbledon absence will stretch into a third year after the Australian tennis maverick suffered a fresh injury setback. Kyrgios hasn't played at Wimbledon since losing the 2022 final to Novak Djokovic, after a combination of knee, foot and wrist injuries. He had hoped to play doubles at the French Open with Jordan Thompson but withdrew from what would have been his first appearance at Roland Garros since 2017 with a knee injury. On Tuesday, Kyrgios confirmed that problem would also rule him out of Wimbledon. "Just wanted to give everyone a quick update - l've hit a small setback in my recovery and unfortunately won't make it back for grass season this year," Kyrgios wrote on Instagram. "I know how much you've all been looking forward to seeing me out there, and I'm genuinely sorry to disappoint. "This is just a bump in the road though, and I'm already working hard to get back stronger than ever. "Thank you for all your continued support - it means everything to me. See you soon!" Now 30, Kyrgios faces an uphill battle to resurrect his career, which has been hammered by injuries since late 2022. The former world No.13 has played only four singles matches this year, claiming his first tour victory in two-and-a-half years at the Miami Open in March. His Wimbledon withdrawal means his first-round exit at this year's Australian Open will remain his only grand slam appearance - of a possible 11 - since the start of 2023. Last week, Thompson gave an insight into how much Kyrgios had struggled with his luckless injury run. "He was pretty down. He told me he doesn't know how much more of these injuries he can take, and you've just got to feel for him," Thompson said. "Because as much as he says things in the media, I think he loves playing tennis and he loves being on court, so it's disappointing that he can't be here on the court." Nick Kyrgios's Wimbledon absence will stretch into a third year after the Australian tennis maverick suffered a fresh injury setback. Kyrgios hasn't played at Wimbledon since losing the 2022 final to Novak Djokovic, after a combination of knee, foot and wrist injuries. He had hoped to play doubles at the French Open with Jordan Thompson but withdrew from what would have been his first appearance at Roland Garros since 2017 with a knee injury. On Tuesday, Kyrgios confirmed that problem would also rule him out of Wimbledon. "Just wanted to give everyone a quick update - l've hit a small setback in my recovery and unfortunately won't make it back for grass season this year," Kyrgios wrote on Instagram. "I know how much you've all been looking forward to seeing me out there, and I'm genuinely sorry to disappoint. "This is just a bump in the road though, and I'm already working hard to get back stronger than ever. "Thank you for all your continued support - it means everything to me. See you soon!" Now 30, Kyrgios faces an uphill battle to resurrect his career, which has been hammered by injuries since late 2022. The former world No.13 has played only four singles matches this year, claiming his first tour victory in two-and-a-half years at the Miami Open in March. His Wimbledon withdrawal means his first-round exit at this year's Australian Open will remain his only grand slam appearance - of a possible 11 - since the start of 2023. Last week, Thompson gave an insight into how much Kyrgios had struggled with his luckless injury run. "He was pretty down. He told me he doesn't know how much more of these injuries he can take, and you've just got to feel for him," Thompson said. "Because as much as he says things in the media, I think he loves playing tennis and he loves being on court, so it's disappointing that he can't be here on the court." Nick Kyrgios's Wimbledon absence will stretch into a third year after the Australian tennis maverick suffered a fresh injury setback. Kyrgios hasn't played at Wimbledon since losing the 2022 final to Novak Djokovic, after a combination of knee, foot and wrist injuries. He had hoped to play doubles at the French Open with Jordan Thompson but withdrew from what would have been his first appearance at Roland Garros since 2017 with a knee injury. On Tuesday, Kyrgios confirmed that problem would also rule him out of Wimbledon. "Just wanted to give everyone a quick update - l've hit a small setback in my recovery and unfortunately won't make it back for grass season this year," Kyrgios wrote on Instagram. "I know how much you've all been looking forward to seeing me out there, and I'm genuinely sorry to disappoint. "This is just a bump in the road though, and I'm already working hard to get back stronger than ever. "Thank you for all your continued support - it means everything to me. See you soon!" Now 30, Kyrgios faces an uphill battle to resurrect his career, which has been hammered by injuries since late 2022. The former world No.13 has played only four singles matches this year, claiming his first tour victory in two-and-a-half years at the Miami Open in March. His Wimbledon withdrawal means his first-round exit at this year's Australian Open will remain his only grand slam appearance - of a possible 11 - since the start of 2023. Last week, Thompson gave an insight into how much Kyrgios had struggled with his luckless injury run. "He was pretty down. He told me he doesn't know how much more of these injuries he can take, and you've just got to feel for him," Thompson said. "Because as much as he says things in the media, I think he loves playing tennis and he loves being on court, so it's disappointing that he can't be here on the court." Nick Kyrgios's Wimbledon absence will stretch into a third year after the Australian tennis maverick suffered a fresh injury setback. Kyrgios hasn't played at Wimbledon since losing the 2022 final to Novak Djokovic, after a combination of knee, foot and wrist injuries. He had hoped to play doubles at the French Open with Jordan Thompson but withdrew from what would have been his first appearance at Roland Garros since 2017 with a knee injury. On Tuesday, Kyrgios confirmed that problem would also rule him out of Wimbledon. "Just wanted to give everyone a quick update - l've hit a small setback in my recovery and unfortunately won't make it back for grass season this year," Kyrgios wrote on Instagram. "I know how much you've all been looking forward to seeing me out there, and I'm genuinely sorry to disappoint. "This is just a bump in the road though, and I'm already working hard to get back stronger than ever. "Thank you for all your continued support - it means everything to me. See you soon!" Now 30, Kyrgios faces an uphill battle to resurrect his career, which has been hammered by injuries since late 2022. The former world No.13 has played only four singles matches this year, claiming his first tour victory in two-and-a-half years at the Miami Open in March. His Wimbledon withdrawal means his first-round exit at this year's Australian Open will remain his only grand slam appearance - of a possible 11 - since the start of 2023. Last week, Thompson gave an insight into how much Kyrgios had struggled with his luckless injury run. "He was pretty down. He told me he doesn't know how much more of these injuries he can take, and you've just got to feel for him," Thompson said. "Because as much as he says things in the media, I think he loves playing tennis and he loves being on court, so it's disappointing that he can't be here on the court."


The Advertiser
14 hours ago
- The Advertiser
Surgery risk flagged for popular weight-loss, diabetes drugs in new warning
Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here. Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here. Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here. Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here.